Clinical Trials in Peoria Illinois

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1

Dry Needling in Subjects With Delayed Onset Muscle Soreness
NCT03876080
Condition: Delayed Onset Muscle Soreness
Interventions: Other: Dry needling; Other: Sham needling
Sponsor: Bradley University
Recruiting
Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
NCT03746015
Condition: Dengue Fever
Intervention: Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
Sponsor: Takeda
Recruiting
Hydroxyurea Optimization Through Precision Study
NCT03789591
Conditions: Sickle Cell Disease; Sickle Cell Anemia
Intervention: Drug: Hydroxyurea
Sponsors: Children's Hospital Medical Center, Cincinnati; Doris Duke Charitable Foundation
Recruiting
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
NCT03382405
Condition: Cytomegalovirus Infection
Interventions: Biological: mRNA-1647; Biological: mRNA-1443; Other: Placebo
Sponsor: ModernaTX, Inc.
Recruiting
Work Ability in Young Adult Cancer Survivors
NCT03148080
Condition: Cancer Survivor
Interventions: Procedure: Cognitive Assessment; Other: Questionnaire Administration
Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI)
Recruiting
Clinical Evaluation of a Vascular Venous Anastomotic Connector
NCT02532621
Condition: End Stage Renal Disease
Intervention: Device: Venous InterGraft Connector
Sponsor: Phraxis, Inc.
Recruiting
Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer
NCT03811002
Conditions: Limited Stage Lung Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Drug: Atezolizumab; Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide; Radiation: Intensity-Modulated Radiation Therapy; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
NCT03768414
Conditions: Stage III Distal Bile Duct Cancer AJCC v8; Stage III Gallbladder Cancer AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Distal Bile Duct Cancer AJCC v8; Stage IIIA Gallbladder Cancer AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Distal Bile Duct Cancer AJCC v8; Stage IIIB Gallbladder Cancer AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Gallbladder Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Gallbladder Cancer AJCC v8; Stage IVB Gallbladder Cancer AJCC v8; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Drug: Nab-paclitaxel
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
NCT03712605
Conditions: Pathologic Stage I Merkel Cell Carcinoma AJCC v8; Pathologic Stage II Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8; Pathologic Stage III Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8; Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8; Resected Mass
Interventions: Other: Best Practice; Biological: Pembrolizumab; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia
NCT03701282
Conditions: CCND1/IGHG1 Fusion Negative; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; t(11;14) Negative
Interventions: Drug: Ibrutinib; Biological: Obinutuzumab; Other: Quality-of-Life Assessment; Drug: Venetoclax
Sponsor: National Cancer Institute (NCI)
Recruiting
Gemcitabine Hydrochloride and Cisplatin in Treating Participants With Invasive Bladder Urothelial Cancer
NCT03609216
Conditions: Infiltrating Bladder Urothelial Carcinoma; Stage II Bladder Urothelial Carcinoma; Stage III Bladder Urothelial Carcinoma
Interventions: Drug: Gemcitabine Hydrochloride; Drug: Cisplatin; Biological: Pegfilgrastim; Procedure: Conventional Surgery; Procedure: Radical Cystectomy; Other: Chemoradiotherapy
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT03418961
Conditions: Cardiotoxicity; HER2/Neu Positive; Metastatic Malignant Neoplasm in the Brain; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Drug: Carvedilol; Other: Laboratory Biomarker Analysis; Other: Patient Observation
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT03414970
Conditions: Ductal Breast Carcinoma; Invasive Breast Carcinoma; Lobular Breast Carcinoma; Medullary Breast Carcinoma; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Tubular Breast Carcinoma
Interventions: Radiation: Radiation Therapy; Other: Questionnaire Administration; Other: Quality-of-Life Assessment; Other: Laboratory Biomarker Analysis; Radiation: Hypofractionated Radiation Therapy
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181
Conditions: Adult Germ Cell Tumor; Childhood Extracranial Germ Cell Tumor; Childhood Germ Cell Tumor; Extragonadal Embryonal Carcinoma; Grade 2 Ovarian Teratoma; Malignant Germ Cell Tumor; Malignant Ovarian Teratoma; Stage I Ovarian Choriocarcinoma; Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7; Stage I Ovarian Teratoma AJCC v6 and v7; Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7; Stage I Testicular Choriocarcinoma AJCC v6 and v7; Stage I Testicular Embryonal Carcinoma AJCC v6 and v7; Stage I Testicular Yolk Sac Tumor AJCC v6 and v7; Stage II Ovarian Choriocarcinoma; Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7; Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7; Stage II Testicular Choriocarcinoma AJCC v6 and v7; Stage II Testicular Embryonal Carcinoma AJCC v6 and v7; Stage II Testicular Yolk Sac Tumor AJCC v6 and v7; Stage III Ovarian Choriocarcinoma; Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7; Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7; Stage III Testicular Choriocarcinoma AJCC v6 and v7; Stage III Testicular Embryonal Carcinoma AJCC v6 and v7; Stage III Testicular Yolk Sac Tumor AJCC v6 and v7; Stage IV Ovarian Choriocarcinoma; Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7; Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7; Testicular Mixed Choriocarcinoma and Embryonal Carcinoma; Testicular Mixed Choriocarcinoma and Teratoma; Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
Interventions: Other: Best Practice; Drug: Bleomycin; Biological: Bleomycin Sulfate; Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide; Drug: Etoposide Phosphate; Other: Laboratory Biomarker Analysis; Other: Pharmacogenomic Study; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer
NCT03244384
Conditions: Stage II Bladder Urothelial Carcinoma AJCC v6 and v7; Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Interventions: Other: Clinical Observation; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab; Other: Pharmacological Study; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Recruiting
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711
Conditions: Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Anal Margin Squamous Cell Carcinoma; Stage IIB Anal Cancer AJCC v8; Stage IIIA Anal Cancer AJCC v8; Stage IIIB Anal Cancer AJCC v8; Stage IIIC Anal Cancer AJCC v8
Interventions: Biological: Nivolumab; Other: Patient Observation
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
NCT03228537
Conditions: Biphasic Mesothelioma; Epithelioid Mesothelioma; Stage I Pleural Malignant Mesothelioma AJCC v7; Stage IA Pleural Malignant Mesothelioma AJCC v7; Stage IB Pleural Malignant Mesothelioma AJCC v7; Stage II Pleural Malignant Mesothelioma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7
Interventions: Drug: Atezolizumab; Drug: Cisplatin; Procedure: Extrapleural Pneumonectomy; Drug: Pemetrexed Disodium; Procedure: Pleurectomy; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Non-metastatic Colorectal Cancer Receiving Chemotherapy
NCT03186638
Conditions: Caregiver; Cognitive Impairment; Stage 0 Colorectal Cancer AJCC v6 and v7; Stage I Colorectal Cancer AJCC v6 and v7; Stage II Colorectal Cancer AJCC v7; Stage IIA Colorectal Cancer AJCC v7; Stage IIB Colorectal Cancer AJCC v7; Stage IIC Colorectal Cancer AJCC v7; Stage III Colorectal Cancer AJCC v7; Stage IIIA Colorectal Cancer AJCC v7; Stage IIIB Colorectal Cancer AJCC v7; Stage IIIC Colorectal Cancer AJCC v7
Interventions: Drug: Ibuprofen; Other: Placebo; Other: Questionnaire Administration
Sponsors: Gary Morrow; National Cancer Institute (NCI)
Recruiting
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
NCT03087708
Conditions: Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer
Interventions: Drug: Naloxegol; Other: Placebo; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NCT03070886
Conditions: Stage I Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma
Interventions: Drug: Bicalutamide; Drug: Docetaxel; Radiation: External Beam Radiation Therapy; Drug: Flutamide; Drug: Goserelin Acetate; Other: Laboratory Biomarker Analysis; Drug: Leuprolide Acetate; Drug: Nilutamide
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
NCT02927249
Condition: Node Positive HER2 Negative Breast Cancer
Interventions: Other: Placebo; Drug: Aspirin
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); United States Department of Defense; Bayer; Canadian Cancer Trials Group
Recruiting
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
NCT02921256
Conditions: Rectal Adenocarcinoma; Stage II Rectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7
Interventions: Drug: Capecitabine; Drug: Fluorouracil; Radiation: Intensity-Modulated Radiation Therapy; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Biological: Pembrolizumab; Drug: Veliparib
Sponsor: National Cancer Institute (NCI)
Recruiting
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
NCT02912559
Conditions: Colon Adenocarcinoma; DNA Repair Disorder; Lynch Syndrome; Stage III Colon Cancer AJCC v7; Stage IIIA Colon Cancer AJCC v7; Stage IIIB Colon Cancer AJCC v7; Stage IIIC Colon Cancer AJCC v7
Interventions: Drug: Atezolizumab; Drug: Fluorouracil; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Recruiting
Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes
NCT02856581
Condition: Lung Carcinoma
Interventions: Drug: Varenicline; Drug: Placebo; Other: Tobacco Cessation Counseling
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Pfizer
Recruiting
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02834013
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
S0820, Adenoma and Second Primary Prevention Trial
NCT01349881
Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo; Drug: eflornithine & sulindac placebo; Drug: Eflornithine placebo & sulindac; Drug: Eflornithine plus sulindac
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Cancer Prevention Pharmaceuticals, Inc.
Recruiting
Cabozantinib S-Malate, Crizotinib, Savolitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
NCT02761057
Conditions: Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7; Type 1 Papillary Renal Cell Carcinoma; Type 2 Papillary Renal Cell Carcinoma; Unresectable Renal Cell Carcinoma
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Drug: Crizotinib; Drug: Savolitinib; Drug: Sunitinib; Drug: Sunitinib Malate
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Breast Cancer WEight Loss Study (BWEL Study)
NCT02750826
Condition: Breast Carcinoma
Interventions: Other: Health Education Program; Other: Weight Loss Intervention
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Division of Cancer Control; NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP); Canadian Cancer Trials Group
Recruiting
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT02562716
Conditions: Pancreatic Adenocarcinoma; Resectable Pancreatic Carcinoma
Interventions: Drug: Fluorouracil; Drug: Gemcitabine Hydrochloride; Drug: Irinotecan Hydrochloride; Drug: Oxaliplatin; Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Procedure: Pancreatectomy
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967
Conditions: Breast Adenocarcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Progesterone Receptor Negative; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIC Breast Cancer; Triple-Negative Breast Carcinoma
Interventions: Drug: Carboplatin; Drug: Cyclophosphamide; Drug: Doxorubicin Hydrochloride; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
NCT02474160
Conditions: Lymphoma; Malignant Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Plasma Cell Leukemia; Plasma Cell Myeloma; Progressive Disease; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Plasma Cell Myeloma; Spread of Lymphoma
Intervention: Other: Cytology Specimen Collection Procedure
Sponsor: National Cancer Institute (NCI)
Recruiting
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
NCT02466971
Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Stage IB2 Cervical Cancer AJCC v6 and v7; Stage II Cervical Cancer AJCC v7; Stage II Vaginal Cancer AJCC v6 and v7; Stage IIA Cervical Cancer AJCC v7; Stage IIB Cervical Cancer AJCC v6 and v7; Stage III Vaginal Cancer AJCC v6 and v7; Stage IIIB Cervical Cancer AJCC v6 and v7; Stage IVA Cervical Cancer AJCC v6 and v7; Stage IVA Vaginal Cancer AJCC v6 and v7; Vaginal Adenocarcinoma; Vaginal Adenosquamous Carcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions: Drug: Cisplatin; Radiation: External Beam Radiation Therapy; Radiation: Intensity-Modulated Radiation Therapy; Radiation: Internal Radiation Therapy; Other: Laboratory Biomarker Analysis; Radiation: Radiation Therapy; Drug: Triapine
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060
Conditions: Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Kidney Carcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Neoplasm; Melanoma; Ovarian Carcinoma; Pancreatic Carcinoma; Plasma Cell Myeloma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Melanoma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Plasma Cell Myeloma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Recurrent Uterine Corpus Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Plasma Cell Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma; Uterine Corpus Cancer
Interventions: Drug: Adavosertib; Drug: Afatinib; Drug: Afatinib Dimaleate; Drug: Binimetinib; Drug: Capivasertib; Drug: Copanlisib; Drug: Copanlisib Hydrochloride; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Drug: Dasatinib; Drug: Defactinib; Drug: Defactinib Hydrochloride; Drug: Erdafitinib; Drug: FGFR Inhibitor AZD4547; Drug: Ipatasertib; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Drug: Larotrectinib Sulfate; Biological: Nivolumab; Drug: Osimertinib; Drug: Palbociclib; Biological: Pertuzumab; Drug: PI3K-beta Inhibitor GSK2636771; Drug: Sapanisertib; Drug: Sunitinib Malate; Drug: Taselisib; Drug: Trametinib; Biological: Trastuzumab; Biological: Trastuzumab Emtansine; Drug: Ulixertinib; Drug: Vismodegib
Sponsor: National Cancer Institute (NCI)
Recruiting
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT02224781
Conditions: BRAF NP_004324.2:p.V600X; Metastatic Melanoma; Progressive Disease; Recurrent Melanoma; Stage III Cutaneous Melanoma AJCC v7; Stage IIIA Cutaneous Melanoma AJCC v7; Stage IIIB Cutaneous Melanoma AJCC v7; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Cutaneous Melanoma
Interventions: Drug: Dabrafenib; Drug: Dabrafenib Mesylate; Biological: Ipilimumab; Biological: Nivolumab; Other: Quality-of-Life Assessment; Drug: Trametinib; Drug: Trametinib Dimethyl Sulfoxide
Sponsor: National Cancer Institute (NCI)
Recruiting
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Conditions: ALK Gene Rearrangement; ALK Gene Translocation; ALK Positive; Stage IB Non-Small Cell Lung Carcinoma AJCC v7; Stage II Non-Small Cell Lung Cancer AJCC v7; Stage IIA Non-Small Cell Lung Carcinoma AJCC v7; Stage IIB Non-Small Cell Lung Carcinoma AJCC v7; Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions: Other: Clinical Observation; Drug: Crizotinib; Other: Laboratory Biomarker Analysis
Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI)
Recruiting
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738
Conditions: Lung Adenocarcinoma; Lung Large Cell Carcinoma; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage IB Lung Squamous Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage II Lung Squamous Cell Carcinoma AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIA Lung Squamous Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Squamous Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
Interventions: Other: Clinical Observation; Drug: Crizotinib; Other: Cytology Specimen Collection Procedure; Drug: Erlotinib Hydrochloride; Biological: Nivolumab; Other: Placebo
Sponsor: National Cancer Institute (NCI)
Recruiting
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282
Conditions: ALK Gene Rearrangement; EGFR Exon 19 Deletion Mutation; EGFR NP_005219.2:p.L858R; Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions: Other: Clinical Observation; Drug: Erlotinib Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Placebo
Sponsor: National Cancer Institute (NCI)
Recruiting
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
NCT02177695
Condition: Bladder Cancer
Interventions: Drug: Gemcitabine; Drug: Cisplatin; Drug: Methotrexate; Drug: Vinblastine; Drug: Doxorubicin; Drug: Filgrastim
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma
NCT02004275
Condition: Multiple Myeloma in Relapse
Interventions: Drug: pomalidomide; Drug: ixazomib; Drug: dexamethasone
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Celgene Corporation; Millennium Pharmaceuticals, Inc.
Recruiting
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
NCT02003222
Conditions: Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative; BCR/ABL1 Fusion Protein Negative; Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Biological: Blinatumomab; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Daunorubicin Hydrochloride; Drug: Dexamethasone; Drug: Etoposide; Other: Laboratory Biomarker Analysis; Drug: Mercaptopurine; Drug: Methotrexate; Drug: Pegaspargase; Drug: Prednisone; Biological: Rituximab; Drug: Vincristine Sulfate
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
NCT01901094
Conditions: Stage II Breast Cancer; Stage IIIA Breast Cancer
Interventions: Procedure: Axillary Lymph Node Dissection (ALND); Radiation: Nodal Radiation Therapy; Radiation: Axillary Radiation Therapy
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
NCT00632853
Condition: Lung Cancer
Interventions: Radiation: Standard Radiation Dose Therapy; Drug: cisplatin; Drug: etoposide; Radiation: High Radiation Dose Therapy; Drug: carboplatin
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva
NCT01595061
Conditions: Stage IIIA Vulvar Cancer AJCC v7; Stage IIIB Vulvar Cancer AJCC v7; Stage IIIC Vulvar Cancer AJCC v7; Stage IVA Vulvar Cancer AJCC v7; Vulvar Squamous Cell Carcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Radiation: Intensity-Modulated Radiation Therapy; Procedure: Therapeutic Conventional Surgery
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery
NCT01101451
Conditions: Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Stage I Cervical Cancer AJCC v6 and v7; Stage IA Cervical Cancer AJCC v6 and v7; Stage IB Cervical Cancer AJCC v6 and v7; Stage IIA Cervical Cancer AJCC v7
Interventions: Drug: Cisplatin; Radiation: External Beam Radiation Therapy; Radiation: Intensity-Modulated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
NCT01042522
Conditions: Ovarian Granulosa Cell Tumor; Ovarian Gynandroblastoma; Ovarian Sertoli-Leydig Cell Tumor; Ovarian Sex Cord Tumor With Annular Tubules; Ovarian Sex Cord-Stromal Tumor; Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types; Ovarian Steroid Cell Tumor
Interventions: Biological: Bleomycin Sulfate; Drug: Carboplatin; Drug: Cisplatin; Drug: Etoposide Phosphate; Other: Laboratory Biomarker Analysis; Drug: Paclitaxel
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
NCT00887146
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: concomitant temozolomide (TMZ); Radiation: radiotherapy; Drug: procarbazine; Drug: adjuvant temozolomide (TMZ); Drug: CCNU; Drug: vincristine
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI); European Organisation for Research and Treatment Center (EORTC); Canadian Cancer Trials Group
Recruiting
BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER
NCT03371719
Conditions: PSA Progression; Stage III Prostate Adenocarcinoma; Stage IV Prostate Adenocarcinoma
Interventions: Drug: Apalutamide; Radiation: External Beam Radiation Therapy; Other: Placebo
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
NCT04001829
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Invasive Breast Carcinoma; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Drug: Docetaxel; Drug: Paclitaxel; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: ECOG-ACRIN Cancer Research Group; National Cancer Institute (NCI)
Recruiting
Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors
NCT03996265
Conditions: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Cancer Fatigue; Cancer Survivor; Complete Remission; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Drug: Bupropion Hydrochloride Controlled-release; Other: Placebo; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Gary Morrow; National Cancer Institute (NCI)
Recruiting
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
NCT03971474
Conditions: Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Drug: Docetaxel; Drug: Gemcitabine; Drug: Gemcitabine Hydrochloride; Biological: Pembrolizumab; Drug: Pemetrexed; Drug: Pemetrexed Disodium; Biological: Ramucirumab
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
NCT03952585
Conditions: Basaloid Squamous Cell Carcinoma; CDKN2A-p16 Positive; Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Oropharyngeal Squamous Cell Carcinoma; Papillary Squamous Cell Carcinoma; Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions: Drug: Cisplatin; Radiation: Image Guided Radiation Therapy; Radiation: Intensity-Modulated Radiation Therapy; Biological: Nivolumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT03866382
Conditions: Bladder Adenocarcinoma; Bladder Mixed Adenocarcinoma; Bladder Small Cell Carcinoma; Bladder Squamous Cell Carcinoma; Bone Lesion; Chromophobe Renal Cell Carcinoma; Infiltrating Bladder Lymphoepithelioma-Like Carcinoma; Infiltrating Bladder Urothelial Carcinoma; Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant; Infiltrating Bladder Urothelial Carcinoma With Giant Cells; Infiltrating Bladder Urothelial Carcinoma, Nested Variant; Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant; Kidney Medullary Carcinoma; Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Carcinoma; Metastatic Bladder Large Cell Neuroendocrine Carcinoma; Metastatic Bladder Small Cell Carcinoma; Metastatic Bladder Squamous Cell Carcinoma; Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant; Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant; Metastatic Kidney Medullary Carcinoma; Metastatic Malignant Genitourinary System Neoplasm; Metastatic Penile Carcinoma; Metastatic Prostate Small Cell Carcinoma; Metastatic Sarcomatoid Renal Cell Carcinoma; Papillary Renal Cell Carcinoma; Sarcomatoid Renal Cell Carcinoma; Stage IV Bladder Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Stage IVA Bladder Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Bladder Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Testicular Leydig Cell Tumor; Testicular Sertoli Cell Tumor
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
NCT03839940
Condition: Malignant Neoplasm
Interventions: Drug: Dexamethasone; Other: Placebo; Other: Questionnaire; Other: Quality-of-Life Assessment; Drug: Everolimus
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer
NCT03811015
Conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Human Papillomavirus-16 Positive; Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Smoker
Interventions: Drug: Cisplatin; Radiation: Intensity-Modulated Radiation Therapy; Biological: Nivolumab; Other: Patient Observation
Sponsor: National Cancer Institute (NCI)
Recruiting
Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
NCT03793179
Conditions: Lung Non-Squamous Non-Small Cell Carcinoma; PD-L1 Positive; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8
Interventions: Drug: Carboplatin; Biological: Pembrolizumab; Drug: Pemetrexed
Sponsor: National Cancer Institute (NCI)
Recruiting
Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer
NCT03793166
Conditions: Clear Cell Renal Cell Carcinoma; Metastatic Malignant Neoplasm in Lymph Node; Metastatic Malignant Neoplasm in the Bone; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Malignant Neoplasm in the Viscera; Sarcomatoid Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8
Interventions: Drug: Cabozantinib; Biological: Ipilimumab; Biological: Nivolumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsor: National Cancer Institute (NCI)
Recruiting
Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)
NCT03737994
Conditions: ALK Gene Rearrangement; ALK Positive; Lung Non-Squamous Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Interventions: Drug: Alectinib; Drug: Brigatinib; Drug: Carboplatin; Drug: Ceritinib; Drug: Cisplatin; Drug: Crizotinib; Drug: Ensartinib; Drug: Lorlatinib; Drug: Pemetrexed
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8; Elevated CA15-3 or CEA or CA27-29
Interventions: Other: Usual care disease monitoring; Other: Serum Tumor Marker directed disease monitoring; Other: Quality-of-Life Assessment; Other: Anxiety Questionnaire Administration
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Genetic Analysis of Blood and Tissue Samples From Participants With Advanced Cancer
NCT03707574
Conditions: Advanced Melanoma; Advanced Renal Cell Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8; Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Stage III Colorectal Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Colorectal Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Ovarian Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIA1 Ovarian Cancer AJCC v8; Stage IIIA2 Ovarian Cancer AJCC v8; Stage IIIB Colorectal Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Ovarian Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Colorectal Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IIIC Ovarian Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8
Intervention: Procedure: Biospecimen Collection
Sponsor: National Cancer Institute (NCI)
Recruiting
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
NCT03701308
Condition: Acute Myeloid Leukemia
Interventions: Drug: Cytarabine; Drug: Daunorubicin; Drug: Uproleselan
Sponsor: National Cancer Institute (NCI)
Recruiting
Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
NCT03698019
Conditions: Acral Lentiginous Melanoma; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Mucosal Melanoma; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions: Biological: Pembrolizumab; Procedure: Therapeutic Conventional Surgery
Sponsor: National Cancer Institute (NCI)
Recruiting
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025
Conditions: Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
Interventions: Drug: Abiraterone; Drug: Bicalutamide; Drug: Degarelix; Drug: Docetaxel; Drug: Flutamide; Drug: Goserelin Acetate; Drug: Histrelin Acetate; Drug: Leuprolide Acetate; Drug: Nilutamide; Procedure: Orchiectomy; Drug: Prednisone; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Procedure: Radical Prostatectomy; Drug: Triptorelin
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia
NCT03654768
Condition: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Drug: Dasatinib; Other: Laboratory Biomarker Analysis; Drug: Nilotinib; Drug: Ruxolitinib Phosphate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
NCT03578081
Condition: Malignant Neoplasm
Interventions: Drug: Palonosetron Hydrochloride; Drug: Ondansetron Hydrochloride; Drug: Dexamethasone; Drug: Fosaprepitant Dimeglumine; Drug: Olanzapine; Other: Placebo
Sponsors: Alliance for Clinical Trials in Oncology; National Cancer Institute (NCI)
Recruiting
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
NCT03499808
Conditions: Amorphous, Eosinophilic, and Acellular Deposit; Constipation; Diarrhea; Early Satiety; Gastrointestinal Hemorrhage; Hepatomegaly; Lymphadenopathy; Macroglossia; Nausea; Primary Systemic Amyloidosis; Purpura; Recurrent Primary Amyloidosis; Refractory Primary Amyloidosis
Interventions: Biological: Isatuximab; Other: Laboratory Biomarker Analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
NCT03367702
Condition: Stage II Prostate Adenocarcinoma
Interventions: Radiation: Intensity-Modulated Radiation Therapy (IMRT); Radiation: Stereotactic Body Radiation Therapy (SBRT)
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin
NCT03258554
Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Head and Neck Squamous Cell Carcinoma; Hypopharyngeal Squamous Cell Carcinoma; Laryngeal Squamous Cell Carcinoma; Oral Cavity Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma; Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Squamous Cell Carcinoma of Unknown Primary; Stage III Hypopharyngeal Carcinoma AJCC v8; Stage III Laryngeal Cancer AJCC v8; Stage III Lip and Oral Cavity Cancer AJCC v8; Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVA Hypopharyngeal Carcinoma AJCC v8; Stage IVA Laryngeal Cancer AJCC v8; Stage IVA Lip and Oral Cavity Cancer AJCC v8; Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8; Stage IVB Hypopharyngeal Carcinoma AJCC v8; Stage IVB Laryngeal Cancer AJCC v8; Stage IVB Lip and Oral Cavity Cancer AJCC v8; Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Biological: Cetuximab; Biological: Durvalumab; Radiation: Intensity-Modulated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group; NRG Oncology
Recruiting
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03137771
Conditions: Recurrent Non-Small Cell Lung Carcinoma; Stage IV Non-Small Cell Lung Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy (3D-CRT); Drug: Docetaxel; Drug: Gemcitabine; Radiation: Intensity-Modulated Radiation Therapy (IMRT); Drug: Pemetrexed Disodium; Radiation: Stereotactic Body Radiation Therapy (SBRT); Drug: Erlotinib Hydrochloride; Drug: Pembrolizumab
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting
Stepped-Care Telehealth for Distress in Rural Cancer Survivors
NCT03060096
Conditions: Anxiety; Depressive Symptoms; Sleep Disturbance; Recurrent Disease; Fatigue; Quality of Life; Cancer
Interventions: Other: Severe Anxiety/depression: High Intensity Stepped Care; Other: Moderate Anxiety/depression: Low Intensity Stepped care; Other: Enhanced Usual Care Control
Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI)
Recruiting
Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer
NCT02635009
Conditions: Extensive Stage Small Cell Lung Carcinoma; Limited Stage Small Cell Lung Carcinoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Other: Cognitive Assessment; Radiation: Intensity-Modulated Radiation Therapy; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsors: NRG Oncology; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT01896999
Conditions: Recurrent Classic Hodgkin Lymphoma; Refractory Classic Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin; Biological: Ipilimumab; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
NCT03204916
Condition: Acute Lymphoblastic Leukemia
Interventions: Other: Medical Chart Review; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial
NCT03699124
Condition: Smallpox
Intervention: Biological: FD MVA-BN
Sponsors: Bavarian Nordic; Biomedical Advanced Research and Development Authority
Recruiting
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
NCT03206450
Conditions: Cancer Survivor; Osteosarcoma
Interventions: Procedure: Biospecimen Collection; Other: Laboratory Biomarker Analysis; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
NCT00492778
Conditions: Endometrial Adenocarcinoma; Endometrial Adenosquamous Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation; Endometrial Serous Adenocarcinoma; Recurrent Uterine Corpus Carcinoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Drug: Cisplatin; Radiation: Intensity-Modulated Radiation Therapy; Radiation: Internal Radiation Therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting
A Study of PRN1008 in Adult Patients With Immune Thrombocytopenic Purpura (ITP)
NCT03395210
Condition: Immune Thrombocytopenic Purpura
Intervention: Drug: PRN1008
Sponsor: Principia Biopharma Inc.
Recruiting
BAX 802 in CHA With Inhibitors
NCT02895945
Condition: Hemophilia A
Intervention: Biological: Antihemophilic Factor (Recombinant), Porcine Sequence (BAX802)
Sponsors: Baxalta now part of Shire; Baxalta Innovations GmbH, now part of Shire
Recruiting
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
NCT03334409
Conditions: Clear Cell Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v7; Unresectable Renal Cell Carcinoma
Interventions: Drug: Ascorbic Acid; Drug: Pazopanib Hydrochloride
Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI)
Recruiting
VasQ External Support for Arteriovenous Fistula
NCT03242343
Conditions: Arterio-Venous Fistula; ESRD; Steal Syndrome; Aneurysm; Renal Failure; Renal Disease; Diabetes Mellitus; Kidney Failure
Intervention: Device: VasQ
Sponsor: Laminate Medical Technologies
Recruiting
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
NCT02628405
Conditions: CD20 Positive; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory Transformed Non-Hodgkin Lymphoma
Interventions: Drug: Carboplatin; Drug: Etoposide; Drug: Ifosfamide; Other: Laboratory Biomarker Analysis; Drug: Lenalidomide; Biological: Rituximab
Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI)
Recruiting
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer
NCT03785925
Conditions: Urinary Bladder Neoplasm; Neoplasm Metastasis
Interventions: Biological: Bempegaldesleukin; Biological: Nivolumab
Sponsors: Nektar Therapeutics; Bristol-Myers Squibb
Recruiting
Electronic Patient Reporting of Symptoms During Cancer Treatment
NCT03249090
Conditions: Advanced Cancer; Metastatic Cancer
Interventions: Other: Patient Self-Reporting of Symptoms; Other: Usual Care Delivery
Sponsors: Alliance Foundation Trials, LLC.; Patient-Centered Outcomes Research Institute; University of North Carolina; Mayo Clinic; American Society of Clinical Oncology; American Cancer Society, Inc.; Dana-Farber Cancer Institute
Recruiting
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT03845296
Conditions: Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Loss of Heterozygosity; Lung Non-Small Cell Squamous Carcinoma; Recurrent Large Cell Lung Carcinoma; Recurrent Lung Adenocarcinoma; Recurrent Lung Non-Small Cell Carcinoma; Recurrent Non-Squamous Non-Small Cell Lung Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
Intervention: Drug: Rucaparib
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
NCT03674112
Condition: HER2-Positive Early Breast Cancer
Interventions: Drug: Pertuzumab and Trastuzumab FDC SC; Drug: Pertuzumab IV; Drug: Trastuzumab IV
Sponsor: Hoffmann-La Roche
Recruiting
Apixaban in Preventing Secondary Cancer Related Blood Clots in Cancer Patients Who Have Completed Anticoagulation Therapy
NCT03080883
Conditions: Cerebral Vein Thrombosis; Deep Vein Thrombosis; Malignant Neoplasm; Metastatic Malignant Neoplasm; Pulmonary Embolism; Splanchnic Vein Thrombosis
Intervention: Drug: Apixaban
Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI)
Recruiting
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
NCT03989232
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Semaglutide; Drug: Placebo (semaglutide)
Sponsor: Novo Nordisk A/S
Recruiting
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
Condition: Previously Treated Non-Small Cell Lung Cancer
Intervention: Drug: Screening Platform
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting
Sleep for Stroke Management and Recovery Trial
NCT03812653
Conditions: Ischemic Stroke; Sleep Apnea; Sleep Apnea, Obstructive; TIA; Stroke; CPAP; Telemedicine; Home Sleep Apnea Test; Randomized Clinical Trial; Multicenter Trial
Intervention: Device: CPAP
Sponsors: University of Michigan; National Institute of Neurological Disorders and Stroke (NINDS); FusionHealth LLC; Medical University of South Carolina; University of Cincinnati
Recruiting
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
NCT03775265
Conditions: Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall; Bladder Urothelial Carcinoma; Stage II Bladder Cancer AJCC v8; Stage III Bladder Cancer AJCC v8; Stage IIIA Bladder Cancer AJCC v8
Interventions: Drug: Atezolizumab; Drug: Cisplatin; Drug: Fluorouracil; Drug: Gemcitabine; Drug: Mitomycin; Other: Quality-of-Life Assessment; Radiation: Radiation Therapy; Other: Survey Administration
Sponsor: National Cancer Institute (NCI)
Recruiting
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
NCT03727009
Condition: Hematologic Malignancy
Intervention: Other: Blood Sample Collection
Sponsor: Exact Sciences Corporation
Recruiting
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
NCT03662204
Conditions: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Bladder Cancer; Uterine Cancer; Kidney Cancer; Renal Pelvis Cancer; Pancreatic Cancer; Liver Cancer; Stomach Cancer; Ovarian Cancer; Esophageal Cancer
Intervention: Other: Blood Sample Collection
Sponsor: Exact Sciences Corporation
Recruiting
A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC
NCT03661320
Conditions: Bladder Cancer; Muscle-Invasive Bladder Cancer; BMS-986205
Interventions: Biological: Nivolumab; Drug: BMS-986205; Drug: Gemcitabine; Drug: Cisplatin; Drug: BMS-986205 Placebo
Sponsor: Bristol-Myers Squibb
Recruiting
XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS)
NCT03654885
Condition: Glaucoma
Interventions: Device: XEN group; Procedure: Trabeculectomy
Sponsor: Allergan
Recruiting
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
NCT03263026
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: Enzastaurin Hydrochloride; Other: R-CHOP + placebo
Sponsor: Denovo Biopharma LLC
Recruiting
To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
NCT03595566
Condition: Clostridium Difficile Infection
Interventions: Drug: ridinilazole; Drug: vancomycin
Sponsor: Summit Therapeutics
Recruiting
Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
NCT03488693
Condition: Breast Cancer
Interventions: Radiation: Radiation; Other: No Radiation
Sponsors: Canadian Cancer Trials Group; Alliance for Clinical Trials in Oncology; Eastern Cooperative Oncology Group; NRG Oncology; Southwest Oncology Group
Recruiting
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
NCT03475186
Conditions: Glioblastoma; Radiotherapy; Complications; Cognitive Decline; Chemoradiation
Intervention: Drug: Ramipril
Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI)
Recruiting
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
NCT03473223
Condition: Acute Coronary Syndrome
Interventions: Biological: Apolipoprotein A-I [human] (apoA-I); Other: Placebo
Sponsor: CSL Behring
Recruiting
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
NCT03456063
Condition: Non-Small-Cell Lung
Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Drug: Placebo Comparator; Drug: Nab-paclitaxel; Drug: Pemetrexed; Drug: Carboplatin; Drug: Cisplatin; Drug: Gemcitabine
Sponsor: Hoffmann-La Roche
Recruiting
A Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT03452137
Condition: Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Drug: Atezolizumab; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting
Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
NCT03375320
Conditions: Atypical Carcinoid Tumor; Carcinoid Tumor; Digestive System Neuroendocrine Neoplasm; Functioning Pancreatic Neuroendocrine Tumor; Intermediate Grade Lung Neuroendocrine Neoplasm; Low Grade Lung Neuroendocrine Neoplasm; Lung Atypical Carcinoid Tumor; Lung Carcinoid Tumor; Metastatic Digestive System Neuroendocrine Tumor G1; Neuroendocrine Neoplasm; Non-Functioning Pancreatic Neuroendocrine Tumor; Pancreatic Neuroendocrine Tumor; Serotonin-Producing Pancreatic Neuroendocrine Tumor; Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7; Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7; Stage IV Digestive System Neuroendocrine Tumor AJCC v7
Interventions: Drug: Cabozantinib S-malate; Other: Laboratory Biomarker Analysis; Other: Placebo; Other: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Recruiting
A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab
NCT03368859
Condition: Cancer
Interventions: Drug: Leucovorin; Drug: Fluorouracil - bolus; Drug: Bevacizumab; Drug: Fluorouracil - infusion; Drug: ABT-165; Drug: Irinotecan
Sponsor: AbbVie
Recruiting
TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure
NCT03296813
Condition: Heart Failure
Interventions: Drug: Torsemide; Drug: Furosemide
Sponsors: Duke University; National Heart, Lung, and Blood Institute (NHLBI); Yale University
Recruiting
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NCT03281954
Condition: Triple Negative Breast Cancer
Interventions: Drug: Placebo; Drug: Atezolizumab
Sponsors: NSABP Foundation Inc; Genentech, Inc.; Hoffmann-La Roche
Recruiting
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
NCT03269669
Conditions: Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Recurrent Follicular Lymphoma; Refractory Follicular Lymphoma
Interventions: Drug: Bendamustine; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Doxorubicin Hydrochloride; Drug: Lenalidomide; Biological: Obinutuzumab; Drug: Prednisone; Drug: Umbralisib; Drug: Vincristine; Drug: Vincristine Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
NCT03259074
Condition: Ankylosing Spondylitis
Interventions: Biological: Secukinumab; Biological: GP2017 (adalimumab biosimilar)
Sponsor: Novartis Pharmaceuticals
Recruiting
Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer
NCT03199885
Conditions: Breast Adenocarcinoma; HER2/Neu Positive; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7
Interventions: Drug: Atezolizumab; Drug: Paclitaxel; Biological: Pertuzumab; Other: Placebo; Other: Quality-of-Life Assessment; Biological: Trastuzumab
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Alectinib; Drug: Atezolizumab; Drug: Pemetrexed; Drug: Cisplatin; Drug: Carboplatin; Drug: Gemcitabine; Drug: Entrectinib
Sponsor: Hoffmann-La Roche
Recruiting
Pilot Study to Assess the Efficacy & Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis
NCT03126760
Condition: Relapsing, Remitting Multiple Sclerosis
Interventions: Drug: Repository Corticotropin Injection; Drug: Placebo
Sponsor: Mallinckrodt
Recruiting
Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT03072238
Condition: Metastatic Prostate Cancer
Interventions: Drug: Ipatasertib; Drug: Abiraterone; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03055013
Conditions: Metastatic Malignant Neoplasm in Lymph Node; Metastatic Malignant Neoplasm in the Adrenal Gland; Metastatic Malignant Neoplasm in the Lung; Metastatic Malignant Neoplasm in the Pancreas; Metastatic Malignant Neoplasm in the Skin; Metastatic Malignant Neoplasm in the Soft Tissues; Metastatic Renal Cell Carcinoma; Oligometastasis; Sarcomatoid Renal Cell Carcinoma; Stage II Renal Cell Cancer AJCC v7; Stage III Renal Cell Cancer AJCC v7; Unclassified Renal Cell Carcinoma
Interventions: Procedure: Conventional Surgery; Biological: Nivolumab; Other: Patient Observation; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); Canadian Cancer Trials Group
Recruiting
Heart Failure Optimization Study
NCT03016754
Conditions: Sudden Cardiac Death; Sudden Cardiac Arrest; Heart Failure; Heart Failure Low Output
Intervention: Device: Wearable Cardioverter Defibrillator
Sponsor: Zoll Medical Corporation
Recruiting
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
NCT02997228
Conditions: Colorectal Adenocarcinoma; Mismatch Repair Deficiency; Stage IV Colorectal Cancer AJCC v7; Stage IVA Colorectal Cancer AJCC v7; Stage IVB Colorectal Cancer AJCC v7
Interventions: Drug: Atezolizumab; Biological: Bevacizumab; Drug: Fluorouracil; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NCT02973789
Condition: Nonsmall Cell Lung Cancer
Interventions: Device: NovoTTF-100L; Drug: Immune checkpoint inhibitors or docetaxel
Sponsor: NovoCure Ltd.
Recruiting
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
NCT02954874
Conditions: Estrogen Receptor Negative; HER2/Neu Negative; Invasive Breast Carcinoma; Progesterone Receptor Negative; Stage 0 Breast Cancer AJCC v6 and v7; Stage I Breast Cancer AJCC v7; Stage IA Breast Cancer AJCC v7; Stage IB Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage IIA Breast Cancer AJCC v6 and v7; Stage IIB Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Other: Patient Observation; Biological: Pembrolizumab; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Radiation: Radiation Therapy
Sponsor: National Cancer Institute (NCI)
Recruiting
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
NCT02926911
Conditions: DCIS; Ductal Carcinoma in Situ
Interventions: Other: Guideline Concordant Care; Other: Active Surveillance
Sponsors: Alliance Foundation Trials, LLC.; Patient-Centered Outcomes Research Institute; Duke University; Dana-Farber Cancer Institute; M.D. Anderson Cancer Center; New York University; Washington University School of Medicine
Recruiting
Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer
NCT02923921
Condition: Pancreatic Cancer
Interventions: Biological: Pegilodecakin; Drug: FOLFOX
Sponsors: Eli Lilly and Company; ARMO BioSciences
Recruiting
Registry of Outcomes From AntiReflux Surgery
NCT02923362
Conditions: Gastroesophageal Reflux Disease; Hiatal Hernia
Interventions: Procedure: Laparoscopic Fundoplication; Device: LINX Antireflux
Sponsor: The Heartburn Foundation
Recruiting
ENRICH: Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ICH)
NCT02880878
Conditions: Intracerebral Hemorrhage; Cerebral Hemorrhage; Intracerebral Haemorrhage
Intervention: Procedure: Early Surgical Hematoma Evacuation
Sponsors: Nico Corporation; Emory University
Recruiting
Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil
NCT02822573
Conditions: Cognitive Dysfunction; Memory Impairment
Interventions: Drug: Donepezil 5 mg; Drug: Placebo
Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI)
Recruiting
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
NCT02793583
Conditions: Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma
Interventions: Drug: TGR-1202 + Ublituximab; Drug: TGR-1202; Drug: TGR-1202 + Ublituximab + Bendamustine
Sponsor: TG Therapeutics, Inc.
Recruiting
Standardized Treatment of Pulmonary Exacerbations II
NCT02781610
Condition: Pulmonary Cystic Fibrosis
Intervention: Drug: Standard of care IV antibiotic(s)
Sponsors: Chris Goss; Cystic Fibrosis Foundation; CF Therapeutics Development Network Coordinating Center; Medical University of South Carolina; University of Washington
Recruiting
The National Myelodysplastic Syndromes (MDS) Study
NCT02775383
Condition: Myelodysplastic Syndromes (MDS)
Intervention: Other: Therapeutic
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI)
Recruiting
S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
NCT02728596
Conditions: Febrile Neutropenia; Stage 0 Breast Cancer; Stage 0 Colorectal Cancer; Stage 0 Non-Small Cell Lung Cancer; Stage I Colorectal Cancer; Stage IA Breast Cancer; Stage IA Non-Small Cell Lung Carcinoma; Stage IB Breast Cancer; Stage IB Non-Small Cell Lung Carcinoma; Stage IIA Breast Cancer; Stage IIA Colorectal Cancer; Stage IIA Non-Small Cell Lung Carcinoma; Stage IIB Breast Cancer; Stage IIB Colorectal Cancer; Stage IIB Non-Small Cell Lung Carcinoma; Stage IIC Colorectal Cancer; Stage IIIA Breast Cancer; Stage IIIA Colorectal Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Colorectal Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IIIC Colorectal Cancer; Stage IV Breast Cancer; Stage IV Non-Small Cell Lung Cancer; Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer
Interventions: Other: Preventive Intervention; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI); Patient-Centered Outcomes Research Institute
Recruiting
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
NCT02680574
Conditions: Anemia; Non-dialysis-dependent Chronic Kidney Disease
Interventions: Drug: vadadustat; Drug: darbepoetin alfa
Sponsor: Akebia Therapeutics
Recruiting
Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
NCT02648347
Conditions: Anemia; Non-dialysis-dependent Chronic Kidney Disease
Interventions: Drug: vadadustat; Drug: darbepoetin alfa
Sponsor: Akebia Therapeutics
Recruiting
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944
Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Non-Small Cell Carcinoma AJCC v7; Stage IIB Lung Non-Small Cell Carcinoma AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Intervention: Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02502266
Conditions: Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cediranib; Drug: Cediranib Maleate; Other: Laboratory Biomarker Analysis; Drug: Olaparib; Drug: Paclitaxel; Drug: Pegylated Liposomal Doxorubicin Hydrochloride; Other: Questionnaire Administration; Drug: Topotecan; Drug: Topotecan Hydrochloride
Sponsors: National Cancer Institute (NCI); NRG Oncology
Recruiting
Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy
NCT02275533
Condition: Acute Myeloid Leukemia in Remission
Interventions: Other: Clinical Observation; Other: Laboratory Biomarker Analysis; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry
NCT02271022
Condition: Acute Coronary Syndromes
Intervention: Other: Non-Interventional Study
Sponsor: AstraZeneca
Recruiting
A Study of ABT-165 in Subjects With Solid Tumors
NCT01946074
Condition: Advanced Solid Tumors
Interventions: Drug: paclitaxel; Drug: FOLFIRI; Drug: ABT-165; Drug: ABBV-181
Sponsor: AbbVie
Recruiting
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
NCT02179086
Conditions: Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: photon beam radiation therapy; Radiation: proton beam radiation therapy; Drug: temozolomide; Other: laboratory biomarker analysis
Sponsors: NRG Oncology; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
NCT03698994
Conditions: Advanced Malignant Solid Neoplasm; ARAF Gene Mutation; BRAF Gene Mutation; GNA11 Gene Mutation; GNAQ Gene Mutation; HRAS Gene Mutation; KRAS Gene Mutation; MAP2K1 Gene Mutation; MAPK1 Gene Mutation; NF1 Gene Mutation; NRAS Gene Mutation; Recurrent Ependymal Tumor; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Central Nervous System Neoplasm; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Histiocytic and Dendritic Cell Neoplasm; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Central Nervous System Neoplasm; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Wilms Tumor
Interventions: Other: Pharmacokinetic Study; Drug: Ulixertinib
Sponsor: National Cancer Institute (NCI)
Recruiting
Dimethyl Fumarate (DMF) Observational Study
NCT02047097
Condition: Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
Sponsor: Biogen
Recruiting
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations
NCT03581292
Conditions: Anaplastic Astrocytoma; BRAF V600 Wild Type; Glioblastoma; H3 K27M Negative; Malignant Glioma
Interventions: Radiation: Radiation Therapy; Drug: Temozolomide; Drug: Veliparib
Sponsor: National Cancer Institute (NCI)
Recruiting
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
NCT03533582
Conditions: Childhood Hepatocellular Carcinoma; Childhood Malignant Liver Neoplasm; Elevated Alpha-Fetoprotein; Hepatoblastoma; Hepatocellular Malignant Neoplasm, Not Otherwise Specified; SMARCB1 Gene Mutation
Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Doxorubicin; Drug: Etoposide; Drug: Fluorouracil; Drug: Gemcitabine; Drug: Irinotecan; Other: Laboratory Biomarker Analysis; Drug: Oxaliplatin; Other: Patient Observation; Drug: Sorafenib; Drug: Vincristine Sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
NCT03526250
Conditions: Advanced Malignant Solid Neoplasm; RB1 Positive; Recurrent Childhood Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma
Interventions: Other: Laboratory Biomarker Analysis; Drug: Palbociclib; Other: Pharmacological Study
Sponsor: National Cancer Institute (NCI)
Recruiting
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
NCT03233204
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Deleterious ATM Gene Mutation; Deleterious BRCA1 Gene Mutation; Deleterious BRCA2 Gene Mutation; Deleterious RAD51C Gene Mutation; Deleterious RAD51D Gene Mutation; Histiocytosis; Low Grade Glioma; Malignant Glioma; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Central Nervous System Neoplasm; Refractory Childhood Malignant Germ Cell Tumor; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Rhabdoid Tumor; Wilms Tumor
Intervention: Drug: Olaparib
Sponsor: National Cancer Institute (NCI)
Recruiting
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
NCT03220035
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; BRAF NP_004324.2:p.V600X; Ependymoma; Ewing Sarcoma; Hepatoblastoma; Langerhans Cell Histiocytosis; Malignant Germ Cell Tumor; Malignant Glioma; Osteosarcoma; Peripheral Primitive Neuroectodermal Tumor; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Central Nervous System Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Rhabdoid Tumor; Rhabdomyosarcoma; Soft Tissue Sarcoma; Wilms Tumor
Interventions: Other: Laboratory Biomarker Analysis; Drug: Vemurafenib
Sponsor: National Cancer Institute (NCI)
Recruiting
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
NCT03213704
Conditions: Advanced Malignant Solid Neoplasm; NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Rhabdoid Tumor; Refractory Central Nervous System Neoplasm; Refractory Childhood Malignant Germ Cell Tumor; Refractory Ependymoma; Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Wilms Tumor
Interventions: Drug: Larotrectinib; Drug: Larotrectinib Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
NCT03213691
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; BRAF Gene Mutation; GNA11 Gene Mutation; GNAQ Gene Mutation; Histiocytosis; HRAS Gene Mutation; KRAS Gene Mutation; NF1 Gene Mutation; NRAS Gene Mutation; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Central Nervous System Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma
Interventions: Other: Laboratory Biomarker Analysis; Drug: Selumetinib; Drug: Selumetinib Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
NCT03213678
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Malignant Glioma; Recurrent Central Nervous System Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Central Nervous System Neoplasm; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Rhabdoid Tumor; Stage III Osteosarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; TSC1 Gene Mutation; TSC2 Gene Mutation; Wilms Tumor
Interventions: Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Drug: Samotolisib
Sponsor: National Cancer Institute (NCI)
Recruiting
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
NCT03213665
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; EZH2 Gain of Function; EZH2 Gene Mutation; Histiocytosis; Loss of BRG1 Protein Expression; Loss of INI 1 Protein Expression; Low Grade Glioma; Recurrent Central Nervous System Neoplasm; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Hodgkin Lymphoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Hodgkin Lymphoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Soft Tissue Sarcoma; Rhabdoid Tumor; SMARCA4 Gene Inactivation; SMARCB1 Gene Inactivation; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Wilms Tumor
Interventions: Other: Laboratory Biomarker Analysis; Drug: Tazemetostat
Sponsor: National Cancer Institute (NCI)
Recruiting
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213652
Conditions: Advanced Malignant Solid Neoplasm; ALK Fusion Protein Expression; ALK Gene Mutation; ALK Gene Translocation; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Histiocytosis; Recurrent Childhood Central Nervous System Neoplasm; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Refractory Central Nervous System Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; ROS1 Fusion Positive; ROS1 Gene Mutation; ROS1 Gene Translocation
Interventions: Drug: Ensartinib; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Sponsor: National Cancer Institute (NCI)
Recruiting
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
NCT03210714
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; FGFR1 Gene Mutation; FGFR2 Gene Mutation; FGFR3 Gene Mutation; FGFR4 Gene Mutation; Histiocytosis; Low Grade Glioma; Malignant Glioma; Recurrent Central Nervous System Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Central Nervous System Neoplasm; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Rhabdoid Tumor; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Wilms Tumor
Interventions: Drug: Erdafitinib; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study
Sponsor: National Cancer Institute (NCI)
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03155620
Conditions: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma; Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma; Childhood Langerhans Cell Histiocytosis; Histiocytic Sarcoma; Juvenile Xanthogranuloma; Malignant Glioma; Recurrent Central Nervous System Neoplasm; Recurrent Childhood Ependymoma; Recurrent Childhood Malignant Germ Cell Tumor; Recurrent Childhood Medulloblastoma; Recurrent Childhood Non-Hodgkin Lymphoma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Childhood Soft Tissue Sarcoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Refractory Central Nervous System Neoplasm; Refractory Childhood Malignant Germ Cell Tumor; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Rhabdoid Tumor; Stage III Osteosarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; Wilms Tumor
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Drug: Ensartinib; Drug: Erdafitinib; Other: Laboratory Biomarker Analysis; Drug: Larotrectinib; Procedure: Mutation Carrier Screening; Drug: Olaparib; Drug: Palbociclib; Other: Pharmacological Study; Drug: Samotolisib; Drug: Selumetinib Sulfate; Drug: Tazemetostat; Drug: Ulixertinib; Drug: Vemurafenib
Sponsor: National Cancer Institute (NCI)
Recruiting
Connect® MDS/AML Disease Registry
NCT01688011
Conditions: Myelodysplastic Syndromes; Acute Myeloid Leukemia
Intervention:
Sponsor: Celgene
Recruiting
A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.
NCT03135834
Condition: Meningococcal Vaccine
Interventions: Biological: MenABCWY; Biological: Saline; Biological: rLP2086; Biological: MenACWY-CRM
Sponsor: Pfizer
Recruiting
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
NCT03126916
Conditions: Ganglioneuroblastoma; INRG Stage L2; INRG Stage M; INRG Stage MS; Neuroblastoma; NMYC Gene Amplification; Recurrent Neuroblastoma
Interventions: Biological: Aldesleukin; Procedure: Autologous Hematopoietic Stem Cell Transplantation; Drug: Busulfan; Drug: Carboplatin; Drug: Cisplatin; Drug: Crizotinib; Drug: Cyclophosphamide; Drug: Dexrazoxane Hydrochloride; Biological: Dinutuximab; Drug: Doxorubicin Hydrochloride; Drug: Etoposide Phosphate; Radiation: External Beam Radiation Therapy; Radiation: Iobenguane I-131; Drug: Isotretinoin; Other: Laboratory Biomarker Analysis; Drug: Melphalan; Other: Pharmacological Study; Biological: Sargramostim; Procedure: Therapeutic Conventional Surgery; Drug: Thiotepa; Drug: Topotecan Hydrochloride; Drug: Vincristine Sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
NCT03057626
Conditions: Recurrent Neuroblastoma; Stage 2A Neuroblastoma; Stage 2B Neuroblastoma; Stage 3 Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma
Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147
Conditions: B Acute Lymphoblastic Leukemia; BCR-ABL1 Fusion Protein Expression; Minimal Residual Disease; Philadelphia Chromosome Positive; T Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Daunorubicin Hydrochloride; Drug: Dexamethasone; Drug: Dexrazoxane Hydrochloride; Drug: Doxorubicin; Drug: Etoposide; Biological: Filgrastim; Drug: Ifosfamide; Drug: Imatinib Mesylate; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Mercaptopurine; Drug: Methotrexate; Drug: Methylprednisolone; Drug: Pegaspargase; Drug: Prednisolone; Other: Questionnaire Administration; Drug: Therapeutic Hydrocortisone; Drug: Thioguanine; Drug: Vincristine Sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); University of Milano Bicocca
Recruiting
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
NCT01560637
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: UT-15C (treprostinil diethanolamine)
Sponsor: United Therapeutics
Recruiting
ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)
NCT01534819
Condition: Aortic Aneurysm
Interventions: Device: EndoAnchor™; Procedure: endovascular treament
Sponsor: Medtronic Endovascular
Recruiting
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
NCT02867592
Conditions: Adrenal Cortex Carcinoma; Alveolar Soft Part Sarcoma; Central Nervous System Neoplasm; Childhood Clear Cell Sarcoma of Soft Parts; Clear Cell Sarcoma of Soft Tissue; Ewing Sarcoma; Hepatoblastoma; Hepatocellular Carcinoma; MITF Positive; Osteosarcoma; Recurrent Adrenal Cortex Carcinoma; Recurrent Alveolar Soft Part Sarcoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Hepatocellular Carcinoma; Recurrent Malignant Central Nervous System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Osteosarcoma; Recurrent Renal Cell Carcinoma; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma; Recurrent Thyroid Gland Medullary Carcinoma; Refractory Ewing Sarcoma; Refractory Malignant Central Nervous System Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Osteosarcoma; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma; Renal Cell Carcinoma; Rhabdomyosarcoma; Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma; Solid Neoplasm; Thyroid Gland Medullary Carcinoma; Wilms Tumor
Interventions: Drug: Cabozantinib; Drug: Cabozantinib S-malate; Other: Pharmacological Study
Sponsor: National Cancer Institute (NCI)
Recruiting
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
NCT02724579
Conditions: CTNNB1 Gene Mutation; Medulloblastoma; Wnt Positive
Interventions: Drug: Cisplatin; Drug: Cyclophosphamide; Other: Laboratory Biomarker Analysis; Drug: Lomustine; Radiation: Radiation Therapy; Drug: Vincristine; Drug: Vincristine Sulfate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02567435
Conditions: Alveolar Rhabdomyosarcoma; Botryoid-Type Embryonal Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma; Rhabdomyosarcoma; Sclerosing Rhabdomyosarcoma; Spindle Cell Rhabdomyosarcoma; Untreated Childhood Rhabdomyosarcoma
Interventions: Drug: Cyclophosphamide; Biological: Dactinomycin; Drug: Irinotecan Hydrochloride; Other: Laboratory Biomarker Analysis; Other: Questionnaire Administration; Radiation: Radiation Therapy; Drug: Temsirolimus; Drug: Vincristine Sulfate; Drug: Vinorelbine
Sponsor: National Cancer Institute (NCI)
Recruiting
Project: Every Child for Younger Patients With Cancer
NCT02402244
Conditions: Central Nervous System Neoplasm; Childhood Immature Teratoma; Childhood Langerhans Cell Histiocytosis; Childhood Malignant Neoplasm; Childhood Mature Teratoma; Congenital Mesoblastic Nephroma; Desmoid-Type Fibromatosis; Lymphoproliferative Disorder; Myeloproliferative Neoplasm; Stromal Neoplasm
Interventions: Other: Cytology Specimen Collection Procedure; Other: Medical Chart Review
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Pediatric Obesity Weight Evaluation Registry (POWER) Study
NCT02121132
Conditions: Overweight; Obesity
Intervention:
Sponsors: Children's Hospital Medical Center, Cincinnati; Helen DeVos Children's Hospital; Mayo Clinic; Duke University; National Association of Children's Hospitals and Related Institutions (NACHRI); Penn State Hershey Children's Hospital; UNM Children's Hospital; University of Illinois College of Medicine at Peoria; Children's Hospital Los Angeles; Connecticut Children's Medical Center; Children's Hospital of San Antonio; Ann & Robert H Lurie Children's Hospital of Chicago; Children's Mercy Hospital Kansas City; Arkansas Children's Hospital Research Institute; Florida Hospital for Children; UCSF Benioff Children’s Hospital Oakland; University of Oklahoma; Barbara Bush Children's Hospital at Maine Medical Center; Seattle Children's Hospital; Eastern Maine Medical Center; University of Florida; University of California, Los Angeles; Gramercy Pediatrics; St. Louis Children's Hospital; Children's Hospital at Dartmouth (CHaD) Pediatric Lipid and Weight Management Center; University of Alabama at Birmingham; University of Oklahoma-Tulsa; Fit Kids of Arizona; University of Kentucky; Orlando Health/Arnold Palmer Hospital Center for Digestive Health and Nutrition; Cleveland Clinic Children's
Recruiting
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
NCT00980954
Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); NRG Oncology
Recruiting
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02101853
Condition: B Acute Lymphoblastic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Drug: Asparaginase; Biological: Blinatumomab; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Dexamethasone; Drug: Etoposide; Other: Laboratory Biomarker Analysis; Drug: Leucovorin Calcium; Drug: Mercaptopurine; Drug: Methotrexate; Drug: Mitoxantrone Hydrochloride; Drug: Pegaspargase; Other: Pharmacological Study; Drug: Therapeutic Hydrocortisone; Drug: Thioguanine; Drug: Vincristine Sulfate
Sponsor: National Cancer Institute (NCI)
Recruiting
Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms
NCT00443274
Condition: Breast Implant
Interventions: Other: NBIR Placeholder; Device: 410 Arm; Device: BIFs
Sponsor: Allergan
Recruiting
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
NCT01096368
Conditions: Cellular Ependymoma; Childhood Anaplastic Ependymoma; Childhood Infratentorial Ependymoma; Childhood Supratentorial Ependymoma; Clear Cell Ependymoma; Ependymoma; Newly Diagnosed Childhood Ependymoma; Papillary Ependymoma
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Drug: Carboplatin; Drug: Cisplatin; Other: Clinical Observation; Drug: Cyclophosphamide; Drug: Etoposide; Other: Laboratory Biomarker Analysis; Drug: Vincristine Sulfate Liposome
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
NCT00904241
Conditions: Ganglioneuroblastoma; Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Regional Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma
Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
NCT00082745
Conditions: Cancer Survivor; Cardiovascular Complication; Childhood Malignant Neoplasm
Interventions: Other: Laboratory Biomarker Analysis; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Sickle Cell Clinical Research and Intervention Program
NCT02098863
Condition: Sickle Cell Disease
Intervention:
Sponsors: St. Jude Children's Research Hospital; Methodist Healthcare; University of Memphis School of Public Health; Le Bonheur Children's Hospital; Methodist Adult Comprehensive Sickle Cell Center, Memphis, TN; University of Alabama at Birmingham; Washington University School of Medicine; UTHSC-ORNL Center in Biomedical Informatics; University of Washington Seattle Cancer Care Alliance; Medical College of Wisconsin; University of Tennessee Health Science Center; Children's Hospital of Philadelphia; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting
Protocol for Collecting, Banking and Distributing Human Tissue Samples: St. Jude Children's Research Hospital Tissue Resources Core Facility
NCT01354002
Condition: Normal and Diseased Tissue and Body Fluids Samples
Intervention:
Sponsor: St. Jude Children's Research Hospital
Recruiting
Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis
NCT03801993
Condition: Cystic Fibrosis
Intervention:
Sponsors: Chris Goss; Emory University; University of North Carolina, Charlotte; University of Texas; Cystic Fibrosis Foundation
Recruiting
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
NCT03794349
Conditions: Ganglioneuroblastoma; Recurrent Neuroblastoma; Refractory Neuroblastoma
Interventions: Biological: Dinutuximab; Drug: Eflornithine; Drug: Irinotecan; Biological: Sargramostim; Drug: Temozolomide
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
ACURATE IDE: Safety and Efficacy Study of Acurate Valve for Transcatheter Aortic Valve Replacement
NCT03735667
Condition: Aortic Stenosis
Interventions: Device: ACURATE neo2™ Transfemoral TAVR System; Device: Medtronic CoreValve TAVR System; Device: Edwards SAPIEN 3 TAVR System
Sponsor: Boston Scientific Corporation
Recruiting
Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry: A Nested Study Within an Existing Registry
NCT03603275
Condition: Hemophilia A
Intervention: Drug: Antihemophilic Factor (Kovaltry, BAY81-8973)
Sponsors: Bayer; American Thrombosis and Hemostasis Network
Recruiting
Axitinib and Nivolumab in Treating Patients With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma
NCT03595124
Conditions: Metastatic Renal Cell Carcinoma; Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8; TFE3 Gene Translocation; TFEB Gene Translocation; Unresectable Renal Cell Carcinoma
Interventions: Drug: Axitinib; Biological: Nivolumab
Sponsor: National Cancer Institute (NCI)
Recruiting
A Study in Participants Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
NCT03148418
Condition: Cancer
Intervention: Drug: Atezolizumab
Sponsor: Hoffmann-La Roche
Recruiting
Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
NCT02720744
Conditions: Excessive Daytime Sleepiness; Cataplexy; Narcolepsy
Interventions: Drug: Sodium Oxybate; Drug: Placebo
Sponsor: Flamel Ireland Limited
Recruiting
Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With CF
NCT02677701
Condition: Cystic Fibrosis
Interventions: Drug: azithromycin; Drug: placebo (for azithromycin); Drug: inhaled tobramycin
Sponsors: Seattle Children's Hospital; National Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis Foundation; CF Therapeutics Development Network Coordinating Center
Recruiting
ATHN 2: Factor Switching Study
NCT02546622
Condition: Hemophilia
Interventions: Biological: Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013; Biological: Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013
Sponsors: American Thrombosis and Hemostasis Network; Shire; CSL Behring; Bioverativ Therapeutics Inc.; Bayer
Recruiting
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
NCT01790152
Conditions: Cancer Survivor; Hodgkin Lymphoma in Remission; Leukemia in Remission; Lymphoblastic Lymphoma; Osteosarcoma; Recurrent Leukemia; Recurrent Lymphoma; Recurrent Malignant Neoplasm
Interventions: Other: Assessment of Therapy Complications; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
NCT01442194
Condition: Multiple Sclerosis
Interventions: Drug: other disease-modifying therapy; Drug: Fingolimod
Sponsor: Novartis Pharmaceuticals
Recruiting
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
NCT00781612
Condition: Neoplasm Metastasis
Interventions: Drug: Docetaxel; Drug: Paclitaxel; Drug: Pertuzumab; Drug: Trastuzumab; Drug: Trastuzumab Emtansine
Sponsors: Genentech, Inc.; Hoffmann-La Roche
Recruiting
Neuropsychological and Behavioral Testing in Younger Patients With Cancer
NCT00772200
Conditions: Childhood Malignant Neoplasm; Cognitive Side Effects of Cancer Therapy
Interventions: Procedure: Cognitive Assessment; Other: Quality-of-Life Assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
NCT00736749
Conditions: Acute Lymphoblastic Leukemia; Brain Neoplasm; Hematopoietic Cell Transplantation Recipient; Hodgkin Lymphoma; Osteosarcoma; Rhabdomyosarcoma
Interventions: Procedure: Assessment of Therapy Complications; Other: Questionnaire Administration
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting

Menu

Categories

Recent Listings

Post your clinical trial on JoinClinicalTrials.com

JoinClinicalTrials.com

Results

Post your clinical trial on JoinClinicalTrials.com

Popular Now